Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
State of the Art

Economic Impact of Antimicrobial Resistance

John E. McGowanComments to Author 
Author affiliation: Emory University School of Medicine, Atlanta, Georgia, USA

Main Article

Table 3

Examples of studies of economic impact of resistance published in 1999-2000

Year First author (ref.) Study methods Features measured
2000 Soriano (9) Case-control, cohort Death, length of hospital stay
2000 Roghmann (10) Cohort Mortality rates at 7 and 30 days, length of hospital stay, direct health-care costs
2000 Vanhems (11) Cohort Death
2000 Simor (12) Comparison of cases with arbitrary criteria Incremental length of hospital stay
2000 Harthug (13) Case-control Death
2000 Bhavnani (14) Case-control Death
2000 Feikin (15) Cohort Death
2000 Garbutt (16) Retrospective cohort Death
1999 Carmeli (17) Cohort Death, length of hospital stay, hospital charges
1999 Rubin (18) Modeling, assumption and extrapolation from case reports Death, direct medical costs
1999 Weingarten (19) Case-control Use of ventilators, length of hospital stay, duration and number of antimicrobial agents, hospital and pharmacy charges
1999 Gonzalez (20) Cohort death
1999 Abramson (21) Case-control Length of hospital stay, attributable median total cost

Main Article

References
  1. Institute of Medicine. Antimicrobial drug resistance: issues and options. Workshop report. Washington: National Academy Press, 1998.
  2. Nathwani  D, Malek  M. Cost considerations in the evaluation of new therapies for gram-positive bacteria. Int J Antimicrob Agents. 1999;13:71–8.PubMedGoogle Scholar
  3. Scott  RD, Solomon  SL, McGowan  JE Jr. Applying economic principles to health care. Emerg Infect Dis. 2000;7. In press.PubMedGoogle Scholar
  4. Cohen  ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science. 1992;257:1050–5. DOIPubMedGoogle Scholar
  5. McGowan  JE Jr. Cost and benefit in perioperative antimicrobial prophylaxis-methods for economic analysis. Rev Infect Dis. 1991;13(Suppl 10):S879–89. DOIPubMedGoogle Scholar
  6. Coast  J, Smith  RD, Millar  MR. Superbugs: should antimicrobial drug resistance be included as a cost in economic evaluation? Health Econ. 1996;5:217–26. DOIPubMedGoogle Scholar
  7. Zanetti  G, Platt  R. Cost-effectiveness of vancomycin versus cefazolin for perioperative antibiotic prophylaxis in coronary artery bypass graft surgery [abstract]. Am J Infect Control. 2000;28:79.
  8. Chrischilles  EA, Scholz  DA. Dollars and sense: a practical guide to cost analysis for hospital epidemiology and infection control. Clin Perform Qual Health Care. 1999;7:107–11.PubMedGoogle Scholar
  9. Soriano  A, Martinez  JA, Mensa  J, Marco  F, Almela  M, Moreno-Martinez  A, Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis. 2000;30:368–73. DOIPubMedGoogle Scholar
  10. Roghmann  M, Bradham  D, South  B, Fridkin  S, Perl  TM. The clinical and economic impact of antimicrobial drug resistance on nosocomial bloodstream infections [abstract]. Infect Control Hosp Epidemiol. 2000;21:97.
  11. Vanhems  P, Lepape  A, Savey  A, Jambou  P, Fabry  J. Nosocomial pulmonary infection by antimicrobial-resistant bacteria of patients hospitalized in intensive care units: risk factors and survival. J Hosp Infect. 2000;45:98–106. DOIPubMedGoogle Scholar
  12. Simor  AE, Kim  T, Oh  PI. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals [abstract]. Infect Control Hosp Epidemiol. 2000;21:124.
  13. Harthug  S, Eide  GE, Langeland  N. Nosocomial outbreak of ampicillin resistant Enterococcus faecium: risk factors for infection and fatal outcome. J Hosp Infect. 2000;45:135–44. DOIPubMedGoogle Scholar
  14. Bhavnani  SM, Drake  JA, Forrest  A, Deinhart  JA, Jones  RN, Biedenbach  DJ, A nationwide, multicenter case-control study comparing risk factors, treatment and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000;36:145–58. DOIPubMedGoogle Scholar
  15. Feikin  DR, Schuchat  A, Kolczak  M, Barrett  NL, Harrison  LH, Lefkowitz  L, Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90:223–9. DOIPubMedGoogle Scholar
  16. Garbutt  JM, Ventrapragada  M, Littenberg  B, Mundy  LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis. 2000;30:466–72. DOIPubMedGoogle Scholar
  17. Carmeli  Y, Troillet  N, Karchmer  AW, Samore  MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999;159:1127–32. DOIPubMedGoogle Scholar
  18. Rubin  RJ, Harrington  CA, Poon  A, Dietrich  K, Greene  JA, Moiduddin  A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis. 1999;5:9–17. DOIPubMedGoogle Scholar
  19. Weingarten  CM, Rybak  MJ, Jahns  BE, Stevenson  JG, Brown  WJ, Levine  DP. Evaluation of Acinetobacter baumanii infection and colonization and antimicrobial treatment patterns in an urban teaching hospital. Pharmacotherapy. 1999;19:1080–5. DOIPubMedGoogle Scholar
  20. Gonzalez  C, Rubio  M, Romero-Vivas  J, Gonzalez  M, Picazo  JJ. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis. 1999;29:1171–7. DOIPubMedGoogle Scholar
  21. Abramson  MA, Sexton  DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol. 1999;20:408–11. DOIPubMedGoogle Scholar
  22. Einarsson  S, Kristjansson  M, Kristinsson  KG, Kjartansson  G, Jonsson  S. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: A case-control study. Scand J Infect Dis. 1998;30:253–6. DOIPubMedGoogle Scholar
  23. Ibelings  MM, Bruining  HA. Methicillin-resistant Staphylococcus aureus: acquisition and risk of death in patients in the intensive care unit. Eur J Surg. 1998;164:411–8. DOIPubMedGoogle Scholar
  24. Eandi  M, Zara  GP. Economic impact of resistance in the community. Int J Clin Pract. 1998;95(Suppl):27–38.PubMedGoogle Scholar
  25. Bryce  EA, Tiffin  SM, Isaac-Renton  JL, Wright  CJ. Evidence of delays in transferring patients with methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus to long-term-care facilities. Infect Control Hosp Epidemiol. 2000;21:270–1. DOIPubMedGoogle Scholar
  26. Liss  RH, Batchelor  FR. Economic evaluations of antibiotic use and resistance-a perspective: report of Task Force 6. Rev Infect Dis. 1987;9(Suppl 3):S297–312. DOIPubMedGoogle Scholar
  27. Harris  JD, Samore  M, Carmeli  Y. Control group selection is an important but neglected issue in studies of antibiotic resistance. Ann Intern Med. 2000;133:159.PubMedGoogle Scholar
  28. Rennie  D, Luft  HS. Pharmacoeconomic analyses - making them transparent, making them credible. JAMA. 2000;283:2158–60. DOIPubMedGoogle Scholar
  29. Neumann  PJ, Stone  PW, Chapman  RH, Sandberg  EA, Bell  CM. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med. 2000;132:964–72.PubMedGoogle Scholar
  30. McGowan  JE Jr. Ways and means to influence antimicrobial prescribing in healthcare and its impact on resistance. In: Andremont A, Brun-Buisson C, McGowan JE Jr., editors. Antibiotic therapy and control of antimicrobial drug resistance in hospitals: 6th Maurice Rapin Colloquia. Paris: Elsevier; 1999. p.97-105.
  31. McGowan  JE Jr, Robert  W. Philip Memorial Lecture: Year 2000 bugs--the end of the antibiotic era? Bulletin of the Royal College of Physicians of Edinburgh. In press.
  32. American Society for Microbiology. Report of the ASM Task Force on Antibiotic Resistance. Antimicrob Agents Chemother. 1995;39(Suppl):1–23.PubMedGoogle Scholar
  33. Schlaes  D, Gerding  D, Tenover  F, McGowan  JE Jr, Levy  S, John  J. Guidelines for the prevention of antimicrobial drug resistance in hospitals: joint statement by the Society for Health Care Epidemiology of America and the Infectious Diseases Society of America. Infect Control Hosp Epidemiol. 1997;18:275–91. DOIPubMedGoogle Scholar
  34. Select Committee on Science and Technology, House of Lords. Seventh Report: Resistance to antibiotics and other antimicrobial agents. London: Her Majesty's Stationery Office;1998. Available at URL: http://www.parliament.the-stationery-office.co.uk/pa/ld199798/ldselect/ldsctech/081vii/st0701.htm
  35. Department of Health UK. Government Response to the House of Lords Select Committee on Science & Technology Report: Resistance to antibiotics and other antimicrobial agents (publication CM4172). London: The Stationery Office; 1998.
  36. McGowan  JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol. 1994;15:478–83. DOIPubMedGoogle Scholar
  37. Lai  KK, Kelley  AL, Melvin  ZS, Belliveau  PP, Fontecchio  SA. Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions. Infect Control Hosp Epidemiol. 1998;19:647–52. DOIPubMedGoogle Scholar
  38. Lavin  BS. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry. Infect Control Hosp Epidemiol. 2000;21(Suppl):S32–5. DOIPubMedGoogle Scholar
  39. Moellering  RC Jr. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med. 1999;130:155–7.PubMedGoogle Scholar
  40. Medical Letter. Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther. 2000;42:15–7.PubMedGoogle Scholar
  41. Soriano-Gabarro  M, Besser  R, Schuchat  A. Indications for pneumococcal vaccine in the era of expanding pneumococcal resistance. J Crit Illn. 2000;15:161–4.
  42. Dagan  R, Givon-Lavi  N, Shkolnik  L, Yagupsky  P, Fraser  D. Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: implication for immunizing with conjugate vaccines. J Infect Dis. 2000;181:1322–9. DOIPubMedGoogle Scholar
  43. Wise  R, Andrews  JM. Local surveillance of antimicrobial drug resistance. Lancet. 1998;352:657. DOIPubMedGoogle Scholar
  44. Weinstein  RA. Controlling antimicrobial drug resistance: the role of infection control and antimicrobial use. Program of the 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections. Atlanta, Georgia, March 5-9, 2000:7.
  45. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Tenth Informational Supplement (Publication M100-S10). Villanova, Pennsylvania: NCCLS; 2000. vol. 19.
  46. Austin  DJ, Kristinnson  KG, Anderson  RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A. 1999;96:1152–6. DOIPubMedGoogle Scholar
  47. McGowan  JE Jr. Drug resistance and nosocomial infections: epidemiology and prevention strategies. In: Finch RG, Williams R, editors. Balliere's clinical infectious diseases. London: Balliere Tindall; 1999. p. 177-92.
  48. Schentag  JJ. Antibiotic dosing - does one size fit all? JAMA. 1998;279:159–60. DOIPubMedGoogle Scholar
  49. Fraise  AP. Guidelines for the control of methicillin-resistant Staphylococcus aureus. J Antimicrob Agents Chemother. 1998;42:287–9. DOIPubMedGoogle Scholar
  50. Jacoby  GA. Editorial response: epidemiology of extended-spectrum beta-lactamases. Clin Infect Dis. 1998;27:81–3. DOIPubMedGoogle Scholar
  51. White  AC Jr, Atmar  RL, Wilson  J, Cate  TR, Stager  CE, Greenberg  SB. Effects of requiring prior authorization for selected antimicrobials; expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997;25:230–9. DOIPubMedGoogle Scholar
  52. Burke  JP. Antibiotic resistance - squeezing the balloon? JAMA. 1998;280:1270–1. DOIPubMedGoogle Scholar
  53. Lawton  RM, Fridkin  SK, Gaynes  RP, McGowan  JE Jr, Hospitals  ICARE. Practices to improve antimicrobial use at 47 US hospitals: the status of the 1997 SHEA/IDSA position paper recommendations. Infect Control Hosp Epidemiol. 2000;21:256–9. DOIPubMedGoogle Scholar
  54. Gould  IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother. 1999;43:459–65. DOIPubMedGoogle Scholar
  55. Phelps  CE. Bug/drug resistance: sometimes less is more. Med Care. 1989;27:194–203. DOIPubMedGoogle Scholar
  56. Gerding  DN, Martone  WJ. SHEA conference on antimicrobial drug resistance. Infect Control Hosp Epidemiol. 2000;21:347–51. DOIPubMedGoogle Scholar
  57. Interagency Task Force on antimicrobial drug resistance. Draft public health action plan to combat antimicrobial drug resistance. Part I: domestic issues. Available at website: http://www.cdc.gov/drugresistance/actionplan/index.htm. Atlanta: Centers for Disease Control and Prevention; 2000.
  58. Coast  J, Smith  RD, Millar  MR. An economic perspective on policy to reduce antimicrobial drug resistance. Soc Sci Med. 1998;46:29–38. DOIPubMedGoogle Scholar

Main Article

Correction: On July 2, 2001 the following correction was made to this article in the second sentence of paragraph 1. The word "billion" replaced "million" in the phrase "...U.S.$4 to $5 million."

Page created: May 10, 2011
Page updated: May 10, 2011
Page reviewed: May 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external